MedTrace Logo

Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients

NCT06690450 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-11-15

No results posted yet for this study

Summary

The Objective of this study is to assess the Safety and Tolerability of 200 mg and 100 mg of Venofer Administered to Hemodialysis(HD) Patients.

Conditions

  • Hemodialysis

Interventions

DRUG

Venofer® 200 mg

A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes

DRUG

Venofer® 100 mg

A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.

Sponsors & Collaborators

  • American Regent, Inc.

    lead INDUSTRY

Principal Investigators

  • Carol Duffy, D.O.,FACC · Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2002-01-31
Completion
2002-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06690450 on ClinicalTrials.gov